APONTIS PHARMA Secures Five-Year Distribution and Marketing Deal with Novartis for Asthma Medications

APONTIS PHARMA AG announced a significant partnership with Novartis Pharma GmbH, sealing a five-year agreement to distribute and market two asthma medications, Enerzair® and Atectura®, in Germany. This strategic move is anticipated to enhance APONTIS PHARMA's financial outlook for 2024, with an expected sales contribution of around EUR 9 million and an earnings increase of up to EUR 1.5 million for the financial year.

In response to this agreement, APONTIS PHARMA has revised its 2024 forecast, expecting a boost in sales to EUR 50.7 million and an enhanced EBITDA of EUR 3.3 million. This adjustment reflects the company's optimism in the potential of Enerzair® and Atectura® to improve patient care for those suffering from asthma in Germany. Bruno Wohlschlegel, CEO of APONTIS PHARMA, highlighted the importance of this agreement in continuing their mission to provide patient-oriented care and the role of their multi-channel-based go-to-market model in sealing the deal with Novartis.

The partnership is a continuation of an ongoing cooperation between Novartis and APONTIS PHARMA, expected to leverage APONTIS PHARMA's expertise in the sector and underscore its commitment to enhancing asthma care in the local market.